The global peptide therapeutics market size is calculated at USD 54.57 billion in 2026 and is expected to reach around USD 81.5 billion by 2034, growing at a CAGR of 5.35% for the forecasted period.
Ottawa, Nov. 17, 2025 (GLOBE NEWSWIRE) — The global peptide therapeutics market size was valued at USD 51.81 billion in 2025 and is predicted to hit around USD 81.5 billion by 2034, rising at a 5.35% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
The demand for targeted and personalised medicine, coupled with the high efficacy and safety of peptides, also significantly contributes to market growth.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6244
Key Takeaways
- North America dominated the peptide therapeutics market in 2024, with a revenue of approximately 40%.
- Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
- By type, the branded peptide drugs segment dominated the market in 2024, with a revenue of approximately 70%.
- By type, the generic peptide drugs segment is expected to grow at the fastest CAGR during the forecast period.
- By route of administration, the parenteral segment dominated the market in 2024, with a revenue of approximately 85%.
- By route of administration, the oral segment is expected to grow at the fastest CAGR during the forecast period.
- By application/therapeutic area, the oncology segment dominated the peptide therapeutics market in 2024, with a revenue of approximately 35%.
- By application/therapeutic area, the neurological disorders segment is expected to grow at the fastest CAGR during the forecast period.
- By synthesis technology, the solid phase peptide synthesis (SPPS) segment dominated the market in 2024, with a revenue of approximately 65%.
- By synthesis technology, the hybrid technology segment is expected to grow at the fastest CAGR during the forecast period.
- By distribution channel, the hospital pharmacies segment dominated the peptide therapeutics market in 2024, with a revenue of approximately 50%.
- By distribution channel, the online pharmacies segment is expected to grow at the fastest CAGR during the forecast period.
Market Overview & Potential
The peptide therapeutics market is propelled by increasing demand for personalised medicine, with targeted biologics further stimulating growth. The market involves pharmaceutical drugs made from short chains of amino acids (peptides) that serve as signalling molecules to control biological functions. These drugs are used more frequently in oncology, metabolic disorders, infectious diseases, and cardiovascular conditions because of their high specificity, low toxicity, safety advantages, and ability to replicate natural biological pathways. Advances in peptide synthesis, drug delivery systems, and formulations (oral, injectable, transdermal) are promoting wider adoption.
Key Indicators and Highlights
| Pointers | Valuations | |
| Market Size in 2025 | USD 51.81 Billion | |
| Projected Market Size in 2034 | USD 81.5 Billion | |
| CAGR (2025 – 2034) | 5.35 | % |
| Leading Region | North America by 40% | |
| Market Segmentation | By Type, By Route of Administration, By Application/Therapeutic Area, By Synthesis Technology, By Distribution Channel, By Region | |
| Top Key Players | Amgen Inc., Novo Nordisk A/S, Ipsen Pharma, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Bachem Holding AG, CordenPharma International, PolyPeptide Group, Pepscan Therapeutics, Zealand Pharma, Radius Health, Inc., BioGaia AB, Biocon Limited | |
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What is the Potential Responsible for The Growth of The Peptide Therapeutics Market?
The peptide therapeutics market is driven by the rising prevalence of chronic diseases like cancer and diabetes, increased investment in R&D, and advancements in peptide synthesis and delivery technologies. The ability of peptides to target diseases with high specificity and fewer side effects, along with the growing demand for personalised medicine, further fuels market expansion.
What Are the Growing Trends Associated with the Peptide Therapeutics Market?
Increasing disease prevalence: The growing rates of cancer, metabolic disorders (like diabetes), and other chronic conditions are major drivers for new and effective treatments, increasing demand for peptide therapeutics.
Focus on personalised medicine: Advances in areas like genetic engineering and molecular diagnostics are enabling the development of highly targeted peptide drugs, aligning with the trend towards personalised medicine.
Advancements in oral formulations: A significant trend is the development of oral peptide drugs, which improve patient adherence and accessibility by moving away from traditional injectable methods.
Strategic collaborations: There is a notable increase in partnerships between pharmaceutical companies and research institutions to accelerate the research and development of new peptide-based therapies.
Innovation in synthesis and delivery: Ongoing advancements in peptide synthesis technology and drug delivery systems are enhancing the stability, bioavailability, and efficacy of peptide drugs.
What Is the Growing Challenge in the Peptide Therapeutics Market?
The peptide therapeutics market faces challenges related to complex manufacturing processes, which are resource-intensive and difficult to scale up. Other key challenges include limited stability and poor oral bioavailability, requiring specialised delivery systems like injections and making oral administration difficult. Additionally, the market is impacted by high production costs and a current shortage of manufacturing capacity to meet surging demand.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Regional Analysis
How Did North America Dominate the Peptide Therapeutics Market in 2024?
North America dominated the peptide therapeutics market in 2024, with a revenue of approximately 40%. North America dominates the peptide therapeutics market due to strong R&D, high investment in biopharmaceuticals, and advanced healthcare infrastructure. The US is a major contributor, driven by high FDA approvals and an increasing pipeline of peptide-based drugs for cancer, metabolic disorders, and other chronic diseases. Market growth is expected to continue, fueled by advancements in peptide synthesis, drug delivery technologies, and the growing prevalence of chronic diseases like diabetes.
What Made the Asia Pacific Significantly Grow in The Peptide Therapeutics Market In 2024?
Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The Asia Pacific peptide therapeutics market is a rapidly growing segment. The growth is driven by an increasing chronic disease burden, particularly metabolic disorders like diabetes, and rising healthcare expenditure and investment in R&D across the region. China is expected to show the fastest growth, though other major contributors include Japan and India.
Segmental Insights
By Type,
The branded peptide drugs segment dominated the market in 2024, with a revenue of approximately 70%. Branded peptide drugs dominate the market, driven by high innovation and therapeutic efficacy in treating complex diseases like cancer and metabolic disorders. These drugs offer strong patent protection, extensive clinical validation, and physician trust. Major pharmaceutical companies are investing in novel peptide modifications to improve stability, bioavailability, and targeted delivery, supporting sustained growth in the branded segment.
The generic peptide drugs segment is expected to grow at the fastest CAGR during the forecast period. Generic peptide drugs are gaining traction as patent expiries of key branded products open new market opportunities. They offer cost-effective treatment options for chronic diseases, expanding accessibility across developing and developed regions. Regulatory simplifications and advances in synthetic methods have lowered production costs, encouraging several contract manufacturers and biotech firms to enter this market segment.
By Route of Administration,
The parenteral segment dominated the market in 2024, with a revenue of approximately 85%. Parenteral administration remains the most widely adopted route for peptide therapeutics due to their poor oral bioavailability and susceptibility to enzymatic degradation. Injectable formulations, including subcutaneous and intravenous routes, ensure higher bioactivity and rapid therapeutic response. Innovations in sustained-release injectables and depot formulations are improving patient compliance and extending dosing intervals.
The oral segment is expected to grow at the fastest CAGR during the forecast period. Oral peptide therapeutics represent a growing frontier, driven by research into permeation enhancers, nanoparticle carriers, and protective coating technologies. Despite formulation challenges, successful approvals of oral peptides for diabetes and gastrointestinal disorders demonstrate the potential of this route. Pharmaceutical companies are heavily investing in R&D to overcome absorption barriers and achieve large-scale commercialisation.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
By Application/Therapeutic Area,
The oncology segment dominated the peptide therapeutics market in 2024, with a revenue of approximately 35%. Oncology remains the leading therapeutic area for peptide therapeutics, as peptides offer high selectivity and low toxicity for targeted cancer treatment. Peptide-based drugs are used in tumour targeting, hormone therapy, and cancer immunotherapy. Continuous innovation in peptide conjugates and radiolabeled peptides supports the expansion of personalised cancer therapy options.
The neurological disorders segment is expected to grow at the fastest CAGR during the forecast period. Peptide therapeutics are increasingly used in treating neurological conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis. Their ability to cross the blood–brain barrier with modifications enhances their potential in neuroprotection and signal modulation. The segment is supported by growing investment in neuropeptide research and the development of receptor-targeted peptide formulations.
By Synthesis Technology,
The solid phase peptide synthesis (SPPS) segment dominated the market in 2024, with a revenue of approximately 65%. SPPS is the dominant method for peptide synthesis, offering high purity, scalability, and automation. It enables efficient assembly of complex peptide chains used in drug development and manufacturing. Continuous advancements in resin technology, coupling reagents, and automated synthesisers have improved yields and reduced costs, making SPPS the industry standard.
The hybrid technology segment is expected to grow at the fastest CAGR during the forecast period. Hybrid synthesis combines solid-phase and liquid-phase techniques to achieve both scalability and efficiency in large peptide production. It is increasingly favoured for manufacturing long-chain and cyclic peptides, balancing cost-effectiveness with precision. This approach supports commercial manufacturing of therapeutic peptides while maintaining flexibility in sequence length and structural complexity.
By Distribution Channel,
The hospital pharmacies segment dominated the peptide therapeutics market in 2024, with a revenue of approximately 50%. Hospital pharmacies account for a major share of peptide drug distribution, especially for parenteral and oncology-based treatments. These facilities ensure controlled dispensing, cold-chain maintenance, and administration under medical supervision. The growing number of hospital-based speciality clinics and oncology centres continues to reinforce the dominance of this channel.
The online pharmacies segment is expected to grow at the fastest CAGR during the forecast period. Online pharmacies are emerging as an important distribution channel for peptide therapeutics, driven by digital healthcare expansion and telemedicine adoption. They enhance accessibility for chronic disease patients requiring long-term peptide therapies. Regulatory approvals for e-pharmacies and improvements in cold-chain logistics have boosted consumer confidence and market penetration.
Browse More Insights of Towards Healthcare:
The worldwide peptide-based weight loss medication market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034.
The global peptide receptor radionuclide therapy market size is estimated at US$ 2.34 billion in 2024, is projected to grow to US$ 2.58 billion in 2025, and is expected to reach approximately US$ 6.1 billion by 2034. The market is projected to expand at a compound annual growth rate (CAGR) of 10.06% between 2025 and 2034.
The global peptide synthesis market size is calculated at USD 686.59 million in 2024, grew to USD 774.06 million in 2025, and is projected to reach around USD 2277.59 million by 2034. The market is expanding at a CAGR of 12.74% between 2025 and 2034.
The global biosynthesis peptide drugs market size is estimated at US$ 18.31 billion in 2024, is projected to grow to US$ 19.45 billion in 2025, and is expected to reach around US$ 32.88 billion by 2034. The market is projected to expand at a CAGR of 6.26% between 2025 and 2034.
The global chemical synthesis peptide drugs market size is calculated at US$ 2.57 billion in 2024, grew to US$ 2.74 billion in 2025, and is projected to reach around US$ 4.82 billion by 2034. The market is expanding at a CAGR of 6.54% between 2025 and 2034.
The global GMP peptides market size is calculated at USD 1.3 billion in 2024, grew to USD 1.41 billion in 2025, and is projected to reach around USD 2.9 billion by 2034. The market is expanding at a CAGR of 8.35% between 2025 and 2034.
The global oral proteins & peptides market size is calculated at US$ 8.05 billion in 2024, grew to US$ 9.36 billion in 2025, and is projected to reach around US$ 36.35 billion by 2034. The market is expanding at a CAGR of 16.34% between 2025 and 2034.
Recent Developments
- In August 2025, Novo Nordisk and BioMed X announced the start of a new partnership. The effective oral administration of therapeutic peptides is one of the most important issues facing contemporary drug research, and our collaboration attempts to address it.
- In July 2025, Atombeat Inc., a pioneer in AI for drug discovery, and BioDuro, a reputable Contract Research, Development, and Manufacturing Organisation (CRDMO) with a global reputation, announced a strategic partnership to develop an AI-powered platform for rapid peptide drug development.
Peptide Therapeutics Market Key Players List
- Amgen Inc.
- Novo Nordisk A/S
- Ipsen Pharma
- Eli Lilly and Company
- AstraZeneca PLC
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- F. Hoffmann-La Roche AG
- Novartis AG
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Bachem Holding AG
- CordenPharma International
- PolyPeptide Group
- Pepscan Therapeutics
- Zealand Pharma
- Radius Health, Inc.
- BioGaia AB
- Biocon Limited
Segments Covered in The Report
By Type
- Branded Peptide Drugs
- Generic Peptide Drugs
By Route of Administration
- Parenteral (Injectable)
- Oral
- Transdermal & Others
By Application/Therapeutic Area
- Oncology
- Metabolic Disorders (Diabetes, Obesity)
- Infectious Diseases
- Cardiovascular Disorders
- Neurological Disorders
- Others (Dermatology, Urology, Rare Diseases)
By Synthesis Technology
- Solid Phase Peptide Synthesis (SPPS)
- Liquid Phase Peptide Synthesis (LPPS)
- Hybrid Technology
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6244
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.